来那度胺
多发性骨髓瘤
医学
耐火材料(行星科学)
Carfilzomib公司
肿瘤科
蛋白酶体抑制剂
沙利度胺
硼替佐米
药理学
内科学
癌症研究
物理
天体生物学
作者
Sundar Jagannath,Carolyn C. Jackson,Jordan M. Schecter,Nikoletta Lendvai,Huabin Sun,Muhammad Akram,Nitin Patel,Thomas G. Martin
标识
DOI:10.1080/14712598.2024.2352591
摘要
Introduction Ciltacabtagene autoleucel (cilta-cel), a BCMA-targeting CAR-T therapy, is approved in the United States and Europe for patients with relapsed/refractory multiple myeloma (RRMM) and ≥ 1 prior line of therapy (LOT), including a proteasome inhibitor and an immunomodulatory drug, and are lenalidomide refractory.
科研通智能强力驱动
Strongly Powered by AbleSci AI